|
Bob you are right in spirit. This info has been around a long long time in the neuro-degenerative literature. The "rediscovery" of TDP protein at sites where ALS pathology occurs is slightly novel. but mostly tangential and incremental. I really hate when science journalists use the "B" word: Breakthru...in a context like this. It raises false hopes and in fact , in the end does a disservice to both scientists and patients by overpromising. Moreover in this specific case, there is virtually no evidence that a drug directed at the or reverse TDP protein could control ALS pathology or symptoms. Even if it is a "correct " target , such a drug is 20 years off.
|